RILYT vs SRPT · $1.95B cap vs rev $1.13B
B. Riley Financial Inc. 6.00% Senior Notes Due 2028 (RILYT) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
B. Riley Financial Inc. 6.00% Senior Notes Due 2028 (RILYT) common stock listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
RILYT does not have a complete income-statement cache yet.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
RILYT currently screens at market cap $1.95B. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the RILYT and SRPT stock pages for the full models.
Not investment advice.